Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 39, 2017, Pages E8234-E8243

  Fior, Rita ^a,b   Póvoa, Vanda ^a   Mendes, Raquel V ^a   Carvalho, Tânia ^c   Gomes, António ^d   Figueiredo, Nuno ^e   Ferreira, FerreiraRita ^f  

^a CHAMPALIMAUD CENTRE FOR THE UNKNOWN   (Portugal)

^b Gulbenkian de Ciência   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d HOSPITAL PROF DOUTOR FERNANDO FONSECA   (Portugal)

^e CHAMPALIMAUD CLINICAL CENTER   (Portugal)

^f UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

Author keywords

Chemotherapy functional screening; Colorectal cancer; KRAS; Patient derived xenografts; Zebrafish xenograft

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CELL PROLIFERATION; CHEMOSENSITIVITY; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TOLERANCE; GENE MUTATION; GENETIC HETEROGENEITY; HCT 116 CELL LINE; HKE3 CELL LINE; HT-29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT TANDEM REPEAT; SINGLE CELL ANALYSIS; SW480 CELL LINE; SW620 CELL LINE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR XENOGRAFT; ZEBRA FISH; ANALOGS AND DERIVATIVES; ANIMAL; COLORECTAL TUMOR; DRUG SCREENING; FEMALE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MICE; MICE, INBRED NOD; MICE, SCID; ORGANOPLATINUM COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 85029917670     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1618389114     Document Type: Article

References (50)

1. Hidalgo M, et al. (2014) Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov 4:998–1013.
2. Zon L, Peterson R (2010) The new age of chemical screening in zebrafish. Zebrafish 7:1.
3. White R, Rose K, Zon L (2013) Zebrafish cancer: The state of the art and the path forward. Nat Rev Cancer 13:624–636.
4. Veinotte CJ, Dellaire G, Berman JN (2014) Hooking the big one: The potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis Model Mech 7:745–754.
5. Haldi M, Ton C, Seng WL, McGrath P (2006) Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 9:139–151.
6. Marques IJ, et al. (2009) Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer 9:128.
7. Nicoli S, Ribatti D, Cotelli F, Presta M (2007) Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res 67:2927–2931.
8. Zhao C, et al. (2011) A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. PLoS One 6:e21768.
9. Hewitt RE, et al. (2000) Validation of a model of colon cancer progression. J Pathol 192:446–454, and
10. correction Hewitt RE, et al. Validation of a model of colon cancer progression. J Pathol (2001) 194:507.
11. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85–88.
12. Sadanandam A, et al. (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19:619–625.
13. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646–674.
14. Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248:307–318.
15. Xiao F, et al. (2015) MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/ Smad/Id1 signaling. Oncogene 34:1968–1978.
16. Lai KC, et al. (2015) Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth. J Cell Mol Med 19:474–484.
17. Nguyen DX, Bos PD, Massague J (2009) Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284.
18. Valastyan S, Weinberg RA (2011) Tumor metastasis: Molecular insights and evolving paradigms. Cell 147:275–292.
19. Stoletov K, et al. (2010) Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 123:2332–2341.
20. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; The ESMO Guidelines Working Group (2014) Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–iii9.
21. Ninomiya I, et al. (2004) Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum. Int J Cancer 112:135–142.
22. Colucci G, et al. (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Onco-logico Dell’Italia Meridionale. J Clin Oncol 23:4866–4875.
23. Klampfer L, et al. (2005) Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis. Oncogene 24:3932–3941.
24. Priego S, et al. (2008) Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: A Bcl-2- and superoxide dismutase 2-de-pendent mechanism. Mol Cancer Ther 7:3330–3342.
25. Van Schaeybroeck S, et al. (2014) ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep 7: 1940–1955.
26. Iwamoto M, et al. (2014) Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med 55:2038–2044.
27. Karapetis CS, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765.
28. De Roock W, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820.
29. Chen D, Wei L, Yu J, Zhang L (2014) Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin Cancer Res 20:3472–3484.
30. Grothey A, et al. (2016) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312.
31. Sato T, et al. (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141: 1762–1772.
32. Fujii M, et al. (2016) A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18:827–838.
33. Guyot F, et al. (2005) Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 16:756–761.
34. André T, et al.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351.
35. Hsu H, et al. (2016) Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget 7:22257–22270.
36. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339:1546–1558.
37. Almendro V, Marusyk A, Polyak K (2013) Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 8:277–302.
38. Kreso A, et al. (2013) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339:543–548.
39. Bailey AM, et al. (2014) Implementation of biomarker-driven cancer therapy: Existing tools and remaining gaps. Discov Med 17:101–114.
40. Burstein HJ, et al. (2011) American society of clinical oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29:3328–3330.
41. Montero J, Letai A (2016) Dynamic BH3 profiling-poking cancer cells with a stick. Mol Cell Oncol 3:e1040144.
42. Montero J, et al. (2015) Drug-Induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160:977–989.
43. Young M, Reed KR (2016) Organoids as a model for colorectal cancer. Curr Colorectal Cancer Rep 12:281–287.
44. Tang Q, et al. (2014) Optimized cell transplantation using adult rag2 mutant zebrafish. Nat Methods 11:821–824.
45. Moore JC, et al. (2016) Single-cell imaging of normal and malignant cell engraftment into optically clear prkdc-null SCID zebrafish. J Exp Med 213:2575–2589.
46. Ahmed D, et al. (2013) Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2:e71.
47. Casale F, et al. (2004) Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 50:173–179.
48. Graham M, et al. (2000) Clinical pharmacokinetics of oxaliplatin: A critical review. Proc Am Assoc Cancer Res 6:1205–1218.
49. Limacher J, et al. (2003) Phase I study of high dose 5-fluorouracil and folinic acid in weekly continuous infusions. Cancer Ther 1:203–208.
50. Chabot G (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245–259.